Comparative analysis of excretion of six major compounds of Polygonum orientale L. extract in urine, feces and bile under physiological and myocardial ischemia conditions in rats using UPLC-MS/MS

Antibacterial Activity of Dihydroquercetin Separated from Fructus Polygoni orientalis against Clavibacter michiganensis subsp. sepedonicus via Damaging Cell Membrane

The yield and quality of potato can be severely affected by bacterial ring rot, which is caused by Clavibacter michiganensis subsp. sepedonicus (Cms). Recently, using natural compounds to control bacteria has received more attention. In this study, five antibacterial compounds from ethyl acetate (EtOAc) extract of Fructus Polygoni orientalis (FPO) against Cms were isolated and the most active compound was screened. Five active compounds were identified as 3,3'-di-O-methylellagic acid (1), 3,3'-di-O-methylellagic acid-4-O-β-D-glucopyranoside (2), dihydroquercetin (3), protocatechuic acid (4) and quercetin (5). Compound 3 (dihydroquercetin, DHQ) was confirmed as the most active compound. The diameter of inhibition zone (DIZ), minimum inhibitory concentration (MIC), protective efficiency and curative efficiency of DHQ were 22.50 mm, 0.313 mg/mL, 84.49% and 79.63%, respectively, which exceeded these of thiophanate-methyl (TM) in antibacterial activity assays; this indicated that DHQ had satisfactory antibacterial activities against Cms in vitro and in vivo. Results of cell membrane damage assessments indicated that DHQ could reduce membrane potential (MP), disrupt the cell membrane integrity, and promote the leakage of nucleic acids and proteins. Overall, these findings suggested that DHQ could serve as a promising lead molecular against Cms, which could provide a basis for its further derivatization.

Astragalin: a food-origin flavonoid with therapeutic effect for multiple diseases

Naturally occurring flavonoids have long been utilized as essential templates for the development of novel drugs and as critical ingredients for functional foods. Astragalin (AG) is a natural flavonoid that can be isolated from a variety of familiar edible plants, such as the seeds of green tea, Morus alba L., and Cuscuta chinensis. It is noteworthy that AG has a wide range of pharmacological activities and possesses therapeutic effects against a variety of diseases, covering cancers, osteoarthritis, osteoporosis, ulcerative colitis, mastitis, obesity, diabetes mellitus, diabetic complications, ischemia/reperfusion injury, neuropathy, respiratory diseases, and reproductive system diseases. This article reviewed the natural source and pharmacokinetics of AG and systematically summarized the pharmacological activities and potential mechanisms of AG in treating diverse diseases in order to promote the development of AG as a functional food, in doing so providing references for its clinical application in disease therapy.

Polygonum orientale L. Alleviates Myocardial Ischemia-Induced Injury via Activation of MAPK/ERK Signaling Pathway

Although Polygonum orientale L. (PO) has a beneficial effect on treatment of myocardial ischemia (MI), its mechanism remains unclear. This study aimed to explore the pharmacological mechanism of PO against MI through MAPK signaling pathways. Firstly, the therapeutic effect of PO was evaluated for treatment of MI mice. Using Western blot and immunohistochemistry, the influence of PO on MAPK signaling pathways and cell apoptosis was investigated. Subsequently, one key pathway (ERK) of MAPK signaling pathways was screened out, on which PO posed the most obvious impact. Finally, an inhibitor of ERK1/2 was utilized to further verify the regulatory effect of PO on the MAPK/ERK signaling pathway. It was found that PO could reduce the elevation of the ST segment; injury of heart tissue; the activity of LDH, CK, NOS, cNOS and iNOS and the levels of NO, BNP, TNF-α and IL-6. It is notable that PO could significantly modulate the protein content of p-ERK/ERK in mice suffering from MI but hardly had an effect on p-JNK/JNK and p-p38/p38. Additionally, the expressions of bax, caspase3 and caspase9 were inhibited in heart tissue in the PO-treated group. To evaluate whether ERK1/2 inhibitor (PD98059) could block the effect of PO on treatment of MI, both PO and PD98059 were given to mice with MI. It was discovered that the inhibitor indeed could significantly reverse the regulatory effects of PO on the above indicators, indicating that PO could regulate p-ERK/ERK. This study provides experimental evidence that PO extenuates MI injury, cardiomyocyte apoptosis and inflammation by activating the MAPK/ERK signaling pathway.